

PART VII

REFERENCES

- 1) **Allan S; and Jaffle MD (1992).**
Use of intravenous diltiazem in patients with acute coronary artery disease.
Am. J. Cardiol . 69 (7): 25 B - 29 B.
- 2) **Adrian H. Chester BS, Magdi H. Yacoub (1989).**
Influence of endothelin on human coronary arteries, and, localization of its binding sites.
Am. J. Cardiol 63; 1395 - 1398.
- 3) **Badr KF; Murray JJ; Breyer MD ; Takahashi, K; Inagami T; and Harris RC. (1989).**
Mesangial cell, glomerular and renal vascular responses to endothelin in the rat kidney.
J. Clin. Invest. 83: 336 -342.
- 4) **Beaumont JL; Carlson LA ; and Cooper GR (1970).**
Classification of hyperlipidemias and hyperlipoproteinemias.
Bull. W.H.O. 43 : 891.
- 5) **Bilheimer DW; Ho YK ; and Brows MS (1978).**
Genetics of the low density lipoprotein receptor: Diminished receptor activity in lymphocytes from heterozygotes with familial hypercholesterolemia.
J. Clin. Invest. 61 : 678.
- 6) **Bilheimer DW ; Stone NJ ; and Grundy SM. (1979).**
Metabolic studies in familial hypercholesterolemia: Evidence for a gene dosage effect in vivo.
J. Clin. Invest. 64 : 524.
- 7) **Bloch A; Dinsmore RE ; and Lees RS (1976).**
Coronary angiographic findings in type II and type IV hyperlipoproteinemia.
Lancet I : 928.

- 8) **Bloch, KD; Freidrich SP; Lee ME ;Eddy RL, Shows TB; and Quertermous T. (1989).**
Structural organization and chromosomal assignment of the gene encoding endothelin.
J. Biol. Chem. 264 : 10851 - 10857
- 9) **Bohme E ; Graf H ; and Schultz G. (1978).**
Effects of nitroprusside and other smooth muscle relaxants on cyclic GMP formation in smooth muscle and platelets.
Adv. Cyclic B Nucleotide Res. 9 : 131 - 143.
- 10) **Brown WV, Baginsky ML ; and Ehnholm C. (1977).**
Primary type I and V hyperlipoproteinemia.
In Rifkind MB, and Levy R. I. (eds.) Hyperlipidemia, Diagnosis and Therapy p. 93 New York, Grune and Stratton.
- 11) **Busse, R. et al (1985).**
The role of endothelium in the control of vascular tone.
Basic Res. Cardiol. 80, 475-490.
- 12) **Carew TE; Hayes SB; and Kochinsky T. (1976).**
A mechanism by which high density lipoproteins may slow the atherogenic process.
Lancet 1: 1315.
- 13) **Carlson LA. (1982).**
Fish eye disease : A new familial condition with massive corneal opacity and dyslipoproteinemia.
Eur. J. Clin. Invest. 12 : 41.
- 14) **Carr BR ; and Simpson ER (1981).**
Lipoprotein utilization and cholesterol synthesis by the human fetal adrenal gland.
Endocr. Rev. 2 : 306.

- 15) **Cernacek P, and Stewart D.J. 1989.**
Immuno reactive endothelin in human plasma : marked elevations in patients in cardiogenic shock.
Biochem. Biophys. Res. Commun. 161 : 562 - 567

- 16) **Chand N ; and Altura BM (1981).**
Acetyl choline and bradkynin relax intrapulmonary arteries by acting on endothelial cells : Role in lung vascular disease.
Science 213 : 1376 - 1379.

- 17) **Cherry PD; Furchgott RF; Zawadzki IV; and Jothianandan D (1982).**
The role of endothelial cells in the relaxation of isolated arteries by bradykinin.
Proc. Nat'l. Acad. Sci. U.S.A. 79 : 2106 - 2110.

- 18) **Chester AH ; Dashwood MR ; and Clarke JG (1989).**
Influence of endothelin on human coronary arteries and localization of its binding sites.
Am. J. Cardiol. 63 : 1395 - 1398.

- 19) **Coetzee GA; Vander Westhuyzen DR; and Berger GMB (1982).**
Low density lipoprotein metabolism in cultured fibroblasts from a new group of patients presenting clinically with homozygous familial hypercholesterolemia.
Atherosclerosis 2:303.

- 20) **Connor WE ; and Bristow JD . (1985).**
Coronary heart disease in "coronary heart disease. Prevention, Supplications and treatment."
Connor WE and Bristow JD (eds) p. 1 - 4. Philadelphia, London, Mexico City, New York and Sydney.

- 21) **Connor WE ; Cerqueira MT; and Connor RW (1978).**
The plasma lipids lipoproteins and diet of the Terahumora Indians in Mexico.
Am. J. Clin. Nutr. 31 : 1131.
- 22) **Davis MJ; and Thomas A. (1984).**
Thrombosis and acute coronary artery lesions in sudden cardiac ischemic death.
N. Eng. J. Med. 310 : 1137 - 1140.
- 23) **De Mey JG ; and Vanhoutee PM. (1981).**
Role of the intima in cholinergic and purinergic relaxation of isolated canine femoral arteries.
J. Physiol. (London) 316 : 437 - 455.
- 24) **De Mey JG. and Vanhoutee PM, (1982).**
Heterogenous behaviour of the canine arterial and venous wall.
Circ. Res. 51: 439 - 447.
- 25) **De Nucci; Thomas R; D' Orleans - Juste P;Antunes E; Wolder C; Warner TD ; and Vane JR. (1988).**
Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium derived relaxing factor.
Proc. Nat'l. Acad. Sci. USA, 85: 9797-9800.
- 26) **Dinerman JL and Mehta JL (1990).**
Endothelial, platelet and leucocyte interactions in ischemic heart disease : Insights into potential mechanism and their clinical relevance.
J. Am. Coll. Cardiol. 16 : 207 - 222.
- 27) **Eisenberg S; Bilheimer DW; and Lindgren FT. (1973).**
On the metabolic conversion of very low density lipoprotein to low density lipoprotein.
Biochem. Biophys. Acta. 326 : 361.

- 28) **Emori T; Hirata Y; Ohta K; Shichiri M; and Marumo F.**
(1989).
Secretory mechanism in immunoreactive endothelin in cultured bovine endothelial cells.
Biochem. Biophys. Res. Commun. 160: 93-100.
- 29) **Evans H.G. et al** (1989).
Human red blood cells inhibit endothelium -derived relaxing factor (EDRF) activity.
Eur - J pharmac. 163, 361 - 364.
- 30) **Erza D; Goldstein RE; Czaja JF; and Feusrestein GZ.**
(1989).
Lethal ischemia due to intra-coronary endothelin in pigs.
Am. J. Physiol. 257 : H339 - H343.
- 31) **Falk E.** (1987).
Thrombosis in unstable angina : Pathologic aspects.
In : Mehta JL, (ed) Thrombosis and platelets in myocardial ischemia.
Cardiovasc. Clin. Series, Vol.18. Philadelphia:
Davis FA 137 -149.
- 32) **Felker TE ; Hamilton RL ; and Vigne JL** (1982).
Properties of lipoproteins in blood plasma and liver perfusates of rats with cholestasis.
Gastroenterology. 83 : 652.
- 33) **Firth JD ; Ratcliffe PJ ; Rain AEG ; and Ledingham JGG.** (1988).
Endothelin ; An important factor in acute renal failure.
Lancet 2: 1179 - 82.
- 34) **Fitzgerald DJ; Roy L; Catella F; and Fitzgerald GA.**
(1986).
Platelet activation in unstable coronary disease.
N. Engl. J. Med. 315 : 983 - 9.

- 35) **Fogelman AM ; Hokam MM; and Haberland ME (1982).**
Lipoprotein regulation of cholesterol metabolism in macrophages derived from human monocytes.
J. Biol. Chem. 257 : 14081.
- 36) **Folts JD ; Gallagherk ; and Rowe GG. (1982).**
Blood flow reductions in stenosed canine coronary arteries: Vasospasm or platelet aggregation?
Circulation 65 : 248 - 255.
- 37) **Forman MB ; Kinsley RH ; and Duplessis JP (1982).**
Surgical correction of combined supraaortic and valvular aortic stenosis in homozygous familial hypercholesterolemia.
S. Afr. Med. J. 61 : 579.
- 38) **Francis CW ; Connaghan DG, Scott WL, and Marder VJ. 1987.**
Increased plasma concentration of cross - linked fibrin polymers in acute myocardial infarction.
Circulation 75 : 1170 - 7.
- 39) **Fredrickson DS; Goldstein JL ; and Browns MS. (1978).**
The familial hypercholesterolemia.
In Stanbury JB; Wyngaarden JB; and Fredrickson D.S. (eds) :
The metabolic basis of inherited disease 4th ed., p. 604.
New York, Mc Graw - Hill.
- 40) **Fredrickson, DS ; and Levy RI. (1972).**
Familial hyperlipoproteinemia.
In Stanbubry JB ; Wygaarden JB; and Fredrickson DS (eds):
The Metabolic basis of Inherited Disease , 3rd ed. p. 545.
New York, Mc Graw - Hill.

- 41) **Fredrickson DS ; Levy RI ; and Lees RS. (1967).**
Fat transport in lipoproteins - an intergrated approach to mechanism and disorders.
N. Eng. J. Med. 276 : 32, 94, 148, 215, 273.
- 42) **Fredrickson DS ; Morganroth J ; and Levy RI. (1975).**
Type III hyperlipoproteinemia: An analysis of two contemporary definitions.
Ann. Inter. Med. 82 : 150.
- 43) **Furchgott RF (1981).**
The requirement for endothelial cells in the relaxation of arteries by acetylcholine and some other vasolidators.
Trends Pharmacol. Sci. 2: 173 - 176.
- 44) **Furchgott, RF. (1983).**
Role of endothelium in responses of vascular smooth muscle.
Circ. Res. 53: 557 - 572.
- 45) **Furchgott RF (1984).**
The role of endothelium in the response of vascular smooth muscle to drugs.
Ann. Rev. Pharmacol. Toxicol. 24 : 175 - 97.
- 46) **Furchgott, RF (1988).**
In: vasodilation: vascular smooth muscle, peptides, autonomic nerves, and, endothelium.
New York, Raven Press,, 401 - 414.
- 47) **Furchgott RF ; Cherry PD ; and Zawadzki IV. (1983).**
Endothelium - dependent relaxation of arteries by acetylcholine, bradykinin and other agents. In vascular neuroeffector mechanism: 4th international symposium, edited by Bevan JA ; Fujiwara M ; Maxwell RA.

- 48) **Furchgott RF and Zawadzki IV. (1980 a).**
Acetylcholine relaxes arterial smooth muscle by releasing a relaxing substance from endothelial cells (abst.).
Fed. Proc. 39 : 581.
- 49) **Furchgott RF; and Zawadzki IV. (1980 b).**
The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine.
Nature 288 : 373 - 376.
- 50) **Furchgott RF; Zawadzki and Cherry PD. (1981).**
Role of endothelium in the vasodilator response to acetylcholine. In vasodilation edited by Vanhoutte P and Lensen I. New York, Raven press, pp. 49 - 66.
- 51) **Furlong, B et al (1987).**
Endothelium - derived relaxing factor inhibits in vitro platelet aggregation.
Br. J. pharmac. 90, 687 - 692.
- 52) **Gagne C ; Moorjani S ; and Brun D. (1979).**
Heterozygous familial hypercholesterolemia : Relationship between plasma lipids, lipoproteins, clinical manifestations and ischemic heart disease in men and women.
Atherosclerosis 34 : 13
- 53) **Ghiselli G; Schaefer EJ; and Gascon P. (1981).**
Type III hyperlipoproteinemia associated with apolipoprotein E deficiency.
Science 214 : 1239.
- 54) **Gillespie MN; Owasoyojo; McMurtry IF; and O'Brien RF. (1986).**
Sustained coronary vasoconstriction provoked by a peptidergic substance released from endothelial cells in culture.
J. Pharmacol. Exp. Ther. 236 : 339 - 343.

- 55) **Gione E; Norum KR; and Glomset JA. (1978).**
Familial Lecithin : Cholesterol acyl transferase deficiency.
In Stanburry; Wyngaarden JB; and Fredrickson D.S.
(eds):The Metabolic Basis of Inherited Disease, 4th ed.
p.589. New York. Mc Graw- Hill.

- 56) **Glueck CJ; Fallat RW ; and Millet F. (1975).**
Familial hyperlipoproteinemia studies in eighteen Kindreds.
Metabolism 24: 1243.

- 57) **Goetz KL; Wang B; Madwed JB; Zhu JL and Leadley RJ. (1988).**
Cardiovascular, renal, and endocrine responses to intravenous endothelin in conscious dogs.
Am. J. Physiol. 83 " : 317 - 326.

- 58) **Goldberg ND; Graff G; Haddox MK; and Moser ME (1978).**
Redox modulation of splenic cell. Soluble guanylate cyclase activity: Activation by hydrophilic and hydrophobic antioxidants represented by ascorbic and dehydroascorbic acids, fatty acid, hydroperoxides, and prostaglandin endoperoxides.
Adv. Cyclic Nucleotide Res. 9: 101 - 130.

- 59) **Goldstein JL; and Brown MS (1977 a).**
Atherosclerosis : the low density lipoprotein receptor hypothesis.
Metabolism 26: 1257.

- 60) **Goldstein JL ; and Brown MS (1977 b).**
The low density lipoprotein pathway and its relation to atherosclerosis.
Ann. Rev. Biochem.c 46: 897.

- 61) **Goldstein JL ; and Brown MS (1982).**
The LDL receptor defect in familial hypercholesterolemia: Implications for pathogenesis and therapy.
Med. Clin. North Am. 66 : 335

- 62) **Goldstein JL; Schrott HG ; and Hazzard WR. (1973).**
Hyperlipidemia in coronary heart disease : Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder combined hyperlipidemia.
J. Clin. Invest. 52: 1544.

- 63) **Golino P; Buja LM; Ashton JH; Kulkarni P; Taiyor A; and Willerson JT. (1988).**
Effect of thromboxane and serotonin receptor antagonists on intracoronary platelet deposition in dogs with experimentally stenosed coronary arteries.
Circulation 78 : 701 - 711.

- 64) **Gordon T ; Castelli WP; and Hjortland MC (1977).**
High density lipoprotein as a protective factor against coronary heart disease.
The Framingham Study.
Am. J. Med. 62 : 707.

- 65) **Goto K; Kasuya Y; Matsuki N; Takuwa Y; Kurihara H; Iskikawa T; Kimura S; Yanagisawa M; and Masaki T.(1989).**
Endothelin activates the dehydropyridine - sensitive, voltage, dependent Ca^{2+} channel in vascular smooth muscle.
Proc. Nat'l. Acad. Sci. USA. 86 : 3915 - 3918.

- 66) **Griffith, T.M. et al (1988).**
Endothelium derived relaxing factor.
J. Am. Coll. Cardiol 12, 797 - 806.

- 67) **Gryglewski, RJ ; Botting RM; and Vane JR. (1988).**
Mediators produced by the endothelial cell.
Hypertension 12: 530 - 548.

- 68) **Gwynne JJ, and Strauss JF. (1982).**
The role of lipoproteins in steroidogenesis and cholesterol metabolism in steroidogenic glands.
Endocr. Rev. 3 : 299.
- 69) **Hamblin TJ (1990).**
Endothelins, chemical messengers with many functions
BMJ 301: 568.
- 70) **Harrison DG; Armstrong ML; Freiman PC ; and Heistad DD. (1987).**
Restoration of endothelium - dependent relaxation by dietary treatment of atherosclerosis.
J. Clin. Invest. 80: 1808 - 1811.
- 71) **Haught H ; Lawson DL ; and Mehta JL . (1992).**
Slow channel calcium blockers attenuate re-oxygenation mediated vascular contraction but augment vascular contraction.
J. Cardiovasc. Pharmacol. 1992.
- 72) **Havel RJ. (1982 a).**
Familial dysbetalipoproteinemia : New aspects of pathogenesis and diagnosis.
Med. Clin. North Am. 66: 441.
- 73) **Havel RJ. (1982 b).**
Treatment of hyperlipidemia : Where do we stand?
Am. J. Med. 73 : 301.
- 74) **Hazzard WR. (1977).**
Primary type III hyperlipidemia.
In Diagnosis and Theraphy, Rifkind BM and Levy RI (eds). p. 137. New York , Grune and Stratton.

- 75) **Hickey KA;Rubanyi G;Paul RJ;and Highsmith RF.,1985**
Characterization of a coronary vasoconstriction produced by endothelial cells in culture.
***Am. J. Physiol.* 248 : c550 - c556**

- 76) **Hidaka H; and Asano T. (1977).**
Stimulation of platelet guanylate cyclase by unsaturated fatty acid peroxides.
***Proc. Nat'l. Acad. Sci. USA* 74: 3657 - 3661.**

- 77) **Ihoue A; Yanagisawa M ; and Kimura S. (1989).**
The human endothelin family : three structurally and pharmacologically distinct isopeptides predicted by three separate genes.
***Proc. Nat'l. Acad. Sci. USA* 86 : 2863 - 2867.**

- 78) **Illingworth DR ; and Connor WE . (1981).**
Disorders of lipid metabolism.
In Felig P., Baxter JD ; and Broadhouse AE (eds) : Endocrinology and Metabolism p. 917. New York , Mc Graw - Hill.

- 79) **Illingworth DR ; and Connor WE (1985).**
Hyperlipidemia and coronary heart disease.
In Connor WC ; and Bristow JD (eds) Coronary Heart Disease prevention, complication and treatment. p. 21. Lippincott JB, Philadelphia, London, Mexico City, New York , St. Louis, Sydney.

- 80) **Illingworth DR; Portman OW, and Whipple LE . (1974).**
Metabolic interrelationship between the lipids of very low, low and high density lipoproteins in the squirrel monkey.
***Biochem. biophys. Acta* 369 : 304.**

- 81) **Ishikawa T; Yanagisawa; Kimura S; Goto K; and Masaki T. (1989).**
Positive inotropic action of novel vasoconstrictor peptide endothelin on guinea pig atria.
***Am. J. Physiol.* 155; H970-H973.**
- 82) **Ishikawa T; Yanagisawa M; Kimura S; Goto K; and Masaki T. (1988).**
Positive chronotropic effects on endothelin, a novel endothelium derived vasoconstrictor peptide.
***Pflugers Arch.* 413 : 108 - 110.**
- 83) **Itoh Y; Yanagisawa M; and Okkubo S. (1988).**
Cloning and sequence analysis of cDNA encoding the precursor of a human endothelium-derived vasoconstrictor peptide, endothelin : identity of human and porcine endothelin.
***FEBS Lett.* 231 : 440 - 444**
Quoted from: Endothelin : biological actions and mechanisms of signal transduction.
Nicholls, MG (ed).
In ACE report 64 (1990) Merck Sharp and Dohme International, Great Britain.
- 84) **Janus ED ; Nicoll AM ; and Turner PR. (1980).**
Kinetic basis of the primary hyperlipoproteinemias: Studies of lipoprotein B turnover in genetically defined subjects.
***Eur. J. Clin. Invest.* 10: 161.**
- 85) **Kane JP ; Hardman DA ; and Paulus HE. (1980).**
Heterogeneity of apolipoprotein B: Isolation of a new species from human chylomicrons.
***Proc. Nat'l. Acad. Sci. USA* 77 : 2645.**

- 86) **Kane JP; Maloy MJ; and Tun P. (1981).**
Normalization of low density lipoprotein levels in heterozygous familial hypercholesterolemia with a combined drug regimen.
N. Eng. J. Med. 304;251

- 87) **Katsuki S; and Murad T. (1977).**
Regulation of adenosine cyclic 3.5 monophosphate levels and contractility in bovine tracheal smooth muscle.
Mol. Pharmacol. 13: 330 - 341.

- 88) **King AJ; Brenner BM ; and Anderson S. (1989).**
Endothelin : a potent renal and systemic vasoconstrictor peptide.
Am. J. Physiol. 256 : F 1051 - 1058.

- 89) **Kloog Y; Ambar I; Sokolovsky M; and Wollberg Z. (1988).**
Sarafotoxins, a novel vasoconstrictor peptide : Phosphoinositide hydrolysis in rat heart and brain.
Science 242 : 268 - 270.

- 90) **Kohno M; Murakawa K; Yanasuri K; Horio T; Kurihara N; and Takeda T. (1989).**
Prolonged blood pressure elevation after endothelin administration in bilaterally nephrectomized rats.
Metabolism 38 : 712 - 13. (in ACE report, 64, January 1990 published by Current Science Ltd., Great Britain).

- 91) **Kohno M; Murakawa K; Yokokawa K; Yanasuri K; Horio T; and Kurihara N; and Takeda T. (1990).**
Production of endothelin by cultured porcine endothelial cells modulation by adrenaline.
J. Hypertension (in press).

- 92) **Kohno M; Yanasuri K; Murakawa K; Yokokawa K; and Takeda T. (1989).**
Release of immunoreactive endothelin from porcine aortic strips (abstract)
Hypertension. 14 : 334.
- 93) **Komuro I; Kurihara H; Sugiyama T; Takaku F; and Yazaki Y. (1988).**
Endothelin stimulates c-fos and c-myc expression and proliferation of vascular smooth muscle cells.
FEBS Lett 238 : 249 - 252.
- 94) **Kon V; Yoshioka T; Fogo A; and Ichikawa I. (1989).**
Glomerular actions of endothelin in vivo.
J. Clin. Invest. 83 : 1762 - 1767.
- 95) **Kovanen PT; Bilheimer DW; and Goldstein JL. (1981).**
A regulatory role of hepatic low density lipoprotein receptors in vivo in the dog.
Proc. Nat'l. Acad. Sci. USA 78: 1194.
- 96) **Krauss RM. (1982).**
Regulation of high density lipoprotein levels.
Med. Clin. North Am. 66: 403.
- 97) **Kurihara H; Yamaoki K; and Nagai R. (1989).**
Endothelin : A potent vasoconstrictor associated with coronary vasospasm.
Life Sci. 44: 1937 - 1943.
- 98) **Kuriyama H; and Suzuki H. (1978).**
The effects of acetylcholine on the membrane and contractile properties of smooth muscle cells of the rabbit superior mesenteric artery.
Br. J. Pharmacol. 64 : 493 : 501.

- 99) **Latour JG; Rousseau G; and ST Jean G. (1989).**
Diltiazem reduces neutrophil accumulation and infarct size in reperfused myocardium.
Circulation 80 (suppl 2). II - 402.
- 100) **Lawson DL; Mehta P; and Mehta JL. (1991).**
Vasoconstrictor and vasorelaxant effects of endothelin-1 on rat aorta.
Clin. Res. 39: 262 A.
- 101) **Lawson DL; Mehta JL; Nichols WW; Mehta P; and Donnelly WH. (1990).**
Superoxide radical - mediated endothelial injury and vasoconstriction in rat thoracic aortic rings.
J. Lab. Clin. Med. 115: 541 - 548.
- 102) **Lee TJ - F. (1982).**
Cholinergic mechanism in the large cat cerebral artery.
Circ. Res. 50 : 870 - 879.
- 103) **Lewis B, (1990).**
Disorders of lipid transport, in oxford textbook of medicine, 2nd (eds.) Weatherall DJ, Ledingham, JGG, and Warrel DD. Oxford Medical Publications, 1990, pages 9 : 108 - 123.
- 104) **Lipid Research Clinics Program. (1984).**
The Lipid research clinics, coronary primary prevention trial results 1. Reduction in incidence of coronary heart disease.
JAMA 251: 351 - 364.
- 105) **Ludmer PL; Selwyn AP; Shook TL; Wayne RR; Mudge GH; Alexander RW; and Ganz P. (1980).**
Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic human coronary arteries.
N. Eng. J. Med. 315 : 1046 - 1051.

- 106) Mac Intyre DE; Pearson JD; and Gordon JL. (1978).**
Localization and stimulation of prostacyclin production in vascular cells.
Nature 271 : 549 - 551.
- 107) Marlette MA (1989).**
Nitric oxide biosynthesis and biological significance.
Trends in Biochem. Sci. 14, 488 - 492.
- 108) Martin J; Pierre T; and David W. (1992).**
Effect of diltiazem slow - release of formulation on silent myocardial ischemia in stable coronary artery disease.
Am. J. Cardiol. 69 (7) : 30B - 35B.
- 109) Martin W. et al (1985).**
Blockade of endothelium - dependent and glyceryl trinitrate - induced relaxation of rabbit aorta by certain ferrous hemoproteins.
J. Pharmac. Exp. Ther - 233, 679 - 685.
- 110) Mehta JL. (1985).**
Influence of calcium - channel blockers on platelet function and arachidonic acid metabolism.
Am. J. Cardiol. 55 : 158B - 168B.
- 111) Mehta JL; and Conti CR. (1989).**
Aspirin in myocardial ischemia: Why , when, and how much?
Clin. Cardiol. 12 : 179 - 184.
- 112) Mehta JL; Dinerman J; Mehta P; Saldeen TGP; Lawson DL; Donnely WH ; and Wallin R. (1989).**
Neutrophil function in ischemic heart disease.
Circulation 79: 549 - 556.
- 113) Mehta JL; Lawson DL; Mehta P; and Saldeen TGP. (1988).**
Increased prostacyclin and thromboxane A₂ biosynthesis in atherosclerosis.
Proc. Nat'l. Acad. Sci. USA 85: 4511 - 4515.

- 114) Mehta JL; Lawson DL; and Nichols WW. (1989 c).**
Attenuated coronary relaxation after reperfusion: Effects of superoxide dismutase and TxA₂ inhibitor U63, 557 A.
Am. J. Physiol. 257 : H1240 - H1246.
- 115) Mehta JL; Lawson DL; Nichols WW; and Mehta P. (1989).**
Modulation of vascular tone by neutrophils : dependence on endothelial integrity.
Am. J. Physiol. 257 : H 1315 - H 1320.
- 116) Mehta P; and Mehta JL. (1979).**
Platelet function studies in coronary artery disease, V: Evidence for enhanced platelet aggregate formation activity in acute myocardial infarction.
Am. J. Cardiol. 43: 757 - 760.
- 117) Mehta JL; Mehta P; and Conti CR. (1980).**
Platelet function studies in coronary heart disease, IX: Increased platelet prostaglandin generation and abnormal platelet sensitivity to prostacyclin and endoperoxide analog in angina pectoris.
Am. J. Cardiol. 46 : 943 - 947.
- 118) Mehta P; Mehta JL; Lawson DL; Krop I; and Letts GL. (1986).**
Leukotriens potentiate the effects of epinephrine and thrombin on human platelet aggregation.
Thromb. Res. 41 : 731 - 738.
- 119) Mehta JL; Mehta P; and Ostrowski N. (1985).**
Increased human platelets alpha₂ adrenergic receptor affinity for agonist in unstable angina.
J. Lab. Clin. Med. 106: 661 - 666.

- 120) **Mehta JL; Nichols WW; Donnelly WH; Lawson DL; Thompson LV; Ter Riet M; and Saldeen TGP. (1989 a).**
Protection by superoxide dismutase from myocardial dysfunction and attenuation of vasodilator reserve following coronary occlusion and reperfusion in dogs.
Circ. Res. 1283 - 1295.
- 121) **Mehta P; Nicolini FA; and Mehta JL. (1991).**
Influence of extracellular calcium on superoxide radical generation in cholesterol poor and cholesterol rich neutrophils: effect of slow channel calcium blockers.
Clin. Res. 39 : 459 A.
- 122) **Mehta JL; William NH; Donnelly MD; and Nichols WW. (1992).**
Endothelial interactions in coronary artery disease.
Am. J. Cardiol. 69 (7) : 8B - 13B.
- 123) **Mellies MJ; Gartside PS; and Glatfelter L. (1980).**
Effect of probucol on plasma cholesterol, high and low density lipoprotein cholesterol and apolipoprotein A₁ and A₂ in adults with primary familial hypercholesterolemia.
Metabolism 29: 956.
- 124) **Mene' P; Simonson MS; and Dunn MJ. (1989).**
Physiology of the mesangium.
Physiol. Rev. 69 : 1347 - 1424.
- 125) **Miller NE. (1982).**
Coronary atherosclerosis and plasma lipoproteins: Epidemiology and pathophysiologic consideration.
J. Cardiovasc. Pharmacol. (Supp. 2) 4: 190.
- 126) **Miller WL; Redfield MM; and Burnett IC. (1989).**
Integrated cardiac, renal and endocrine actions of endothelin.
J. Clin. Invest. 83 : 317 - 320.
- 127) **Miyauchi T; Yanagisawa M; and Tomizawa T. (1989).**

Increased plasma concentrations of endothelin - 1 in acute myocardial infarction.
Lancet ii : 53.

- 128) Moncada S; Herman AG; Higgs EA; and Vane JR. (1977).**

Differential formation of prostacyclin (PGX or PGI₂) by layers of the arterial wall; An explanation of the antithrombotic properties of vascular endothelium.
Thromb. Res. 11 : 323 - 344.

- 129) Moncada S; Korbout R; Bunting S; and Vane J. (1978).**
Prostacyclin is a circulating hormone.
Nature 273 : 767 - 768.

- 130) Moravec Sc; Reynolds EE; Stewart RW; and Bond M. (1989).**

Endothelin is a positive inotropic agent in human and rat heart in vitro.
Biochem. Biophys. Res. Commun. 159: 14 - 18.

- 131) Morton J; and Kern MD. (1992).**

The cellular influences of calcium antagonists on systemic and coronary hemodynamics.
Am. J. Cardiol. 69 (7) : 3B - 7B.

- 132) Muldoon L; Rodland KD; Forsynthe ML; and Magun BE. (1989).**

Stimulation of phosphatidylinositol hydrolysis, diacylglycerol release and gene expression in response to endothelin , a potent new agonist for fibroblasts and smooth muscle cells.
J. Biol. Chem. 264 : 8529 - 8536.

- 133) Murad F; Arnold WP; Mittal CK;and Braugher JM. (1979).**
Properties and regulation of guanylate cyclase and some proposed functions of cyclic GMP.
Adv. Cyclic Nucleotide Res. 11: 175 - 204.

- 134) **Mustard JF; and Pockham MA. (1977).**
Platelets and diabetes mellitus.
N. Engl. J. Med. 297 : 1345 - 1347.
- 135) **Nadeau RA; and Champlain JD. (1979).**
Plasma catecholamine in acute myocardial infarction.
Am. Heart J. 98: 548 - 54.
- 136) **Needleman P; Raz A; Kulkarni PS; Wyche A; and Denny SE. (1978).**
Prostaglandin I₂ synthesis and vascular effects in isolated coronary artery. In: Mechanisms of vasodilatation, edited by Vanhoutte PM; Lensen I; Karger and Basel. pp 122 - 128.
- 137) **Neri Serneri GG; Modesti PA; Fortini A, Abbate R; Lombardi A, and Gensini GP. (1984).**
Platelet receptors in active spontaneous angina.
Lancet ii : 838 - 841.
- 138) **Nichols WW; Mehta JL; Thompson LV; and Donnelly WH. (1988).**
Synergistic effects of LTC₄ and TxA₂ on coronary flow and myocardial function.
Am. J. Physiol. 255 : H153 - H159.
- 139) **Nicolini FA; Wilson AC; Mehta P; and Mehta JL. (1990).**
Comparative platelet inhibitory effects of human neutrophils and lymphocytes.
J. Lab. Clin. Med. 116 : 147 - 152.
- 140) **Nicoll A; Miller NE; and Lewis B. (1980).**
High density lipoprotein metabolism.
Adv. Lipid. Res. 17: 54.

- 141) **Oku H; Tahara A; Hagane H; Toda I; Yasuda M; Akioka K; Teragaki M' Takeuchi K; Takeda T; and Nakao M. (1989).**
Echocardiographic characteristics of old anterior myocardial infarction with R wave development in follow up ECG.
Jap. J. Med. Ultrasonic . 16 (Supp 1) : 427 - 8.
- 142) **Palmer RMJ; Ferrige AG; and Moncada S. (1987).**
Nitric oxide release accounts for the biological activity of endothelium - derived relaxing factor.
Nature 327 : 524 - 6.
- 143) **Pastrenak R.; and, Braunwald, E. (1991).**
Acute myorcardial infarction, in Harrison's principles of Internal Medicine 12th (eds.) Wilson J; Braunwald E; Isselbacher K. et al; Mc Graw-Hill, Inc. 1991, page 954.
- 144) **Peter C; and Duncan JS. (1989).**
Immunoreactive endothelin in human plasma : Marked elevation in cardiogenic shock.
Biochem. Biophys. Commun. 161: 562 - 7.
- 145) **Peter F; and Robert S. (1992).**
The ischemic myocardium: Strategies for preservation and protection.
Am. J. Cardiol. 69 (7) : 1B - 2B.
- 146) **Radomiski MW, et al (1987).**
Endegenous nitric oxide inhibits platelets adhesion to vascular endothelium.
Lancet 11, 1057 - 1058.
- 147) **Rose V; Wilson G; and Steiner G. (1982).**
Familial hypercholesterolemia: Report of coronary death of age 3 years in a homozygous child and prenatal diagnosis in a heterozygous sibling.
J. Pediatr. 100: 757.

- 148) Rubanyi G; and Vanhoutte PM. (1985).**
Hypoxia releases a vasoconstrictor substance from the canine vascular endothelium.
J. Physiol. (Lond.) 364: 45 - 46.
- 149) Rubanyi G, et al. (1986).**
Flow-induced release of endothelium-derived relaxing factor.
Am. J. Physiol, 250, H1145-H1149.
- 150) Sabesin SM. (1982).**
Cholestatic lipoproteins - their pathogenesis and significance.
Gastroenterology 83: 704.
- 151) Saito T; Yanagisawa M; and Miyauchi T. (1989).**
Endothelin in human circulating blood - effects of major surgical stress.
Jpn. J. Pharmacol. 49: 215P.
- 152) Scheffer EJ; Heaton WH; and Wetzel MG. (1982).**
Plasma apolipoprotein A₁ absence associated with a marked reduction of high density lipoproteins and premature coronary artery disease.
Arteriosclerosis 2:16.
- 153) Scheffer EJ; Levy RI ; and Anderson DW. (1978).**
Plasma triglycerides in regulation of high density lipoprotein cholesterol levels.
Lancet 2: 391.
- 154) Scheffer EJ; Zech LAf; and Schwartz DE. (1980).**
Coronary heart disease prevalence and other clinical features in familial high density lipoprotein deficiency (Tangier disease).
Ann. Int. Med. 93 : 261.

- 155) Schultz KD; Bohme E; Krye VW; and Schultz G. (1979).**
Relaxation of hormonally stimulated smooth muscular tissues by the 8 - bromo - derivative of cyclic GMP.
Naunyn Schmiedebergs Arch, Pharmacol. 301 : 1 - 9.
- 156) Shattil SJ; Anaya - Gallinda R; Benett J; Colman RW; and Cooper RA. (1975).**
Platelet hypersensitivity induced by cholesterol incorporation.
J. Clin. Invest. 55: 636 - 643.
- 157) Sherill BC; Innerarity TL; and Mahley RW. (1980).**
Rapid hepatic clearance of the canine lipoproteins containing only the E apoprotein by a high affinity receptor: Identity with chylomicron remnant transport process.
J. Biol. Chem. 255: 1804.
- 158) Shomokawa H; Flavanah NA; Shepherd JT; and Vanhoutte PM. (1989).**
Endothelium dependent inhibition of ergonovin - induced contraction is impaired in porcine coronary arteries with regenerated endothelium.
Circulation 80: 643 - 650.
- 159) Silberberg SD; Poder TC; Lacerda AE; and Brown AM. (1989).**
Endothelin modulates Ca^{++} channels in coronary artery smooth muscle cells.
Biophys. J. 55 : 37a.
- 160) Simonson MS; and Dunn MJ. (1990).**
Endothelin - 1 stimulates contraction of rat glomerular mesangial cells and potentiates B adrenergic - mediated cAMP accumulation.
J. Clin. Invest. "in press" (in ACE report, 64, January 1990, Published by Current Science Ltd., Great Britain.

- 161) **Simonson MS; and Dunn MJ. (1990).**
Endothelin - biological actions and mechanisms of signal transduction. In ACE report, 64, January 1990.
Presented as a service to medicine by Merck sharp and Dohme international, published by Current Science Ltd. Great Britain.
- 162) **Simonson MS; Wann S; and Mene' P. (1989).**
Endothelin stimulates phospholipase C, Na⁺/H⁺exchange, c-fos expression and mitogenesis in rat mesangial cells.
J. Clin. Invest. 83: 708 - 712.
- 163) **Slack J. (1969).**
Risks of ischemic heart disease in familial hypercholesterolemia.
Lancet 2 : 1380.
- 164) **Soutar AK; Myant NB; and Thompson GR. (1977).**
Simultaneous measurement of apolipoprotein B turn over in very low and low density lipoproteins in familial hypercholesterolemia.
Atherosclerosis 28: 247.
- 165) **Stone NY; Levy RI; and Fredrickson DS. (1974).**
Coronary artery disease in 116 kindred with familial type II hypercholesterolemia.
Circulation 49 : 476.
- 166) **Streja D; Steiner G; and Kwitterovich PO. (1978).**
Plasma high density lipoproteins and ischemic heart disease. Studies in a large kindred familial hypercholestorelia.
Ann. Int. Med. 89: 871.

- 167) **Sundberg EE; and Illingworth DR. (1983).**
Effects of hypolipidemic therapy on cholesterol homeostasis in mononuclear cells from patients with heterozygous familial hypercholesterolemia.
Proc. Nat'l. Acad. Sci. USA. 80: 7631.
- 168) **Takuwa N; Takuwa Y; Yanagisawa M; Yamashita K; and Masaki T. (1989).**
A novel vasoactive peptide endothelin stimulates mitogenesis through inositol lipid turn over in Swiss 3T3 fibroblasts.
J. Biol. Chem. 264: 7856 - 7861.
- 169) **Tomobe Y; Miyauchi T; Sailo A; Yanagisawa M; Kimura S; Goto K; and Masaki T. (1988).**
Effects of endothelin on the renal artery from spontaneously hypertensive and Wistar Kyoto rats.
Eur. J. Pharmacol. 152: 373 - 4.
- 170) **Van de Voorde J; and Leusen I. (1983).**
Role of endothelium in the vasodilator response of rat thoracic aorta to histamin.
Eur. J. Pharmacol. 87: 113 - 120.
- 171) **Van Renterghem C; Vigne P; Barhanin J; Schmid - Alliana A; Felin C; and Lazdunski M. (1988).**
Molecular mechanism of action of the vasoconstrictor peptide endothelin.
Biochem. Biophys. Res. Commun. 157: 977 - 985.
- 172) **Vane JR; Botting R; and Masaki T. (1989).**
Endothelin: workshop held in London 5 - 6 December 1988.,
J. Cardiovasc. Pharmacol. 13 (suppl 5).

- 173) Venter JC; Buonassisi V; Bevan S; Heimann S; and Bevan JA. (1975).**
Hormone and neurotransmitter receptors on the intimal endothelium.
Blood vessels 12: 381 - 382.
- 174) Vigne P; Lazdunski M; and Farclin C. (1989).**
The inotropic effect of endothelin - 1 on rat atria involves hydrolysis of phosphatidyl inositol.
FEBS Lett 249: 143 - 146.
- 175) Watanabe T; Suzuki N; Shimamoto N; Fujino M; and Imada A. (1990).**
Endothelin in myocardial infarction.
Nature 344 : 114.
- 176) Weksler BB; Ley CW; and Jaffe EA. (1978).**
Stimulation of endothelial cell prostacyclin production by thrombin, trypsin and the ionophore A 23187.
J. Clin. Invest. 62 : 923 - 930.
- 177) Weksler BB; Marcus AJ; and Jaffe EA. (1977).**
Synthesis of prostaglandin I₂ (prostacyclin) by cultured human and bovine endothelial cells.
Proc. Nat'l. Acad. Sci. USA 74 : 3922 - 3926.
- 178) Wilson DE; and Lees R. (1972).**
Metabolic relationship among the plasma lipoproteins. Reciprocal changes in the concentrations of very low and low density lipoproteins in man.
J. Clin. Invest. 51 : 1051.
- 179) Yanagisawa M; Akihiro I; and Ischikawa T. (1988 b).**
Primary structure, synthesis and biological activity of rat endothelin, and endothelin - derived vasoconstrictor peptide.
Proc. Nat'l. Acad. Sci. USA 85: 6964 - 6967.

- 180) Yanagisawa M; Kurihara H; and Kimura S. (1988 a).**
A novel potent vasoconstrictor peptide produced by vascular endothelial cells.
Nature 332 : 411 - 415.
- 181) Yasuda M; Kohno M; Tahara A; Itagane H; Toda I; Aioka K; Teragaki M; Oku H; Takeuchi K; and Takeda T. (1990).**
Circulating immunoreactive endothelin in ischemic heart disease.
A. Heart J. 119 (4) : 801 - 806.
- 182) Zawadzki IV; Cherry PD; and Furchgott RF. (1980).**
Comparison of endothelium - dependent relaxation of rabbit aorta by A 23187 and by acetylcholine (abstr.).
Pharmacologist. 22: 271.
- 183) Zawadzki IV; Furchgott RF; and Cherry P. (1981).**
The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by substance P (abstr.).
Fed. Proc. 40: 689.
- 184) Zeidel ML; Brady HR; Kone BC; Cullans SR; and Brenner BM. (1989).**
Endothelin: A peptide inhibitor of Na⁺- K⁺ ATPase in intact renal tubular cells.
Am. J. Physiol. 257: C1101 - C1107.
- 185) Zelis R; Mason DT; and Braunwald E. (1970).**
Effects of hyperlipoproteinemias and their treatment on the peripheral circulation.
Bull-W.H.O - 43: 900.
- 186) Zilversmit DB. (1979).**
Atherogenesis : A post prandial phenomenon.
Circulation 60: 473.